Evidence map›Paper›PMID 22989616›Full record

ReviewCytokine & growth factor reviews2013

Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.

Anup Kumar Singh, Rakesh Kumar Arya, Arun Kumar Trivedi, Sabyasachi Sanyal, Rathindranath Baral, Olivier Dormond, David M Briscoe, Dipak Datta

Open access · greenAbstract readReview
In one paragraph

Review in Cytokine & growth factor reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 190 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Targeting p-FGFR1Biomedicines · 2025
    Article
  7. Immunoexpression of CXCL12 and CXCR4 in oral tongue squamous cell carcinoma of young and older patients.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. SDF-1α Promotes Chondrocyte Autophagy through CXCR4/mTOR Signaling Axis.International journal of molecular sciences · 2023
    Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Anup Kumar SinghDrug Target Discovery and Development (DTDD) Division, CSIR-Central Drug Research Institute, Lucknow 226001, India.
Rakesh Kumar Arya
Arun Kumar Trivedi
Sabyasachi Sanyal
Rathindranath Baral
Olivier Dormond
David M Briscoe
Dipak Datta
Central Drug Research Institute · INChittaranjan National Cancer Institute · INHarvard University · USUniversity Hospital of Lausanne · CH

Funding

Vascular Endothelial Growth Factor Receptor Interactions and Allograft RejectionR01AI092305 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI BRISCOE, DAVID M. · 2012 to 2016
$2.8M
VASCULAR ENDOTHELIAL GROWTH FACTOR IN ALLOIMMUNITYR01HL074436 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI BRISCOE, DAVID M. · 2003 to 2007
$2.0M
NHLBI NIH HHS R01 HL074436NIAID NIH HHS R01 AI092305
6 · The paper itself

Abstract

Although chemokines are well established to function in immunity and endothelial cell activation and proliferation, a rapidly growing literature suggests that CXC Chemokine receptors CXCR3, CXCR4 and CXCR7 are critical in the development and progression of solid tumors. The effect of these chemokine receptors in tumorigenesis is mediated via interactions with shared ligands I-TAC (CXCL11) and SDF-1 (CXCL12). Over the last decade, CXCR4 has been extensively reported to be overexpressed in most human solid tumors and has earned considerable attention toward elucidating its role in cancer metastasis. To enrich the existing armamentarium of anti-cancerous agents, many inhibitors of CXCL12-CXCR4 axis have emerged as additional or alternative agents for neo-adjuvant treatments and even many of them are in preclinical and clinical stages of their development. However, the discovery of CXCR7 as another receptor for CXCL12 with rather high binding affinity and recent reports about its involvement in cancer progression, has questioned the potential of "selective blockade" of CXCR4 as cancer chemotherapeutics. Interestingly, CXCR7 can also bind another chemokine CXCL11, which is an established ligand for CXCR3. Recent reports have documented that CXCR3 and their ligands are overexpressed in different solid tumors and regulate tumor growth and metastasis. Therefore, it is important to consider the interactions and crosstalk between these three chemokine receptors and their ligand mediated signaling cascades for the development of effective anti-cancer therapies. Emerging evidence also indicates that these receptors are differentially expressed in tumor endothelial cells as well as in cancer stem cells, suggesting their direct role in regulating tumor angiogenesis and metastasis. In this review, we will focus on the signals mediated by this receptor trio via their shared ligands and their role in tumor growth and progression.

Indexed as

Receptor Cross-TalkCell Transformation, NeoplasticChemokine CXCL11Chemokine CXCL12HumansNeoplasm MetastasisNeovascularization, PathologicReceptors, CXCRReceptors, CXCR3Receptors, CXCR4Signal TransductionACKR3 protein, humanChemokine CXCL11Chemokine CXCL12CXCL11 protein, humanCXCL12 protein, humanCXCR3 protein, humanCXCR4 protein, humanReceptors, CXCRReceptors, CXCR3Receptors, CXCR4

Identifiers

PMID22989616
PMCPMC4172454
OpenAlexW2015439707

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.